Tardive Dyskinesia: New Treatments for an Old Ailment
This activity outlines evidence-based treatment, individualize treatment choices, and appropriate treatment regimens for patients with tardive dyskinesia.

Tardive Dyskinesia: New Treatments for an Old Ailment

John Kane, M.D.

This activity outlines evidence based treatment, individualize treatment choices, and appropriate treatment regimens for patients with tardive dyskinesia.

Educational Objectives

After completing this activity, the participant should be better able to:
  • Discuss the diagnosis and management of TD in psychiatric patients.
  • Identify psychiatric patients at risk for TD, during routine examinations.
  • Individualize treatment choices, giving consideration to efficacy, safety, long-term data, and unique patient characteristics.
  • Formulate appropriate treatment regimens considering the emergence of new innovative agents.

Accreditation Statement

This activity has been reviewed and is approved for a maximum of 1.0 AAPA Category 1 CME credit by the AAPA Review Panel. Participants should only claim credit commensurate with their participation in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Approval is valid until January 31, 2019.

Program Developer

Developed by Medicine and Global Medical Education and AAPA.

Disclosure Policy Statement

It is the policy of AAPA to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following:

John Kane, M.D.
Chairman of Psychiatry
Hofstra Northwell School of Medicine
Hempstead, New York
Disclosures: Consultant - Alkermes, Intracellular Therapies, Lundbeck, Neurocrine, Otsuka, Pierre Fabre, Takeda, Teva; Speaker’s Bureau - Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest (Allergan), Genentech, Lundbeck, Intracellular Therapies, Janssen, Johnson & Johnson, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, Teva; Research Support - Janssen, Otsuka; Stock Ownership - MedAvante, LB Pharma, Vanguard Research Group

Activity Planners and Managers

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following Global Medical Education Planner, Prakash Masand, M.D., has disclose the following: Consulting Fees from Allergan, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, and Takeda; Research Support from Allergan, and Merck; and Speaker’s Bureau from Allergan, GlaxoSmithKline, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, and Takeda.

Off-Label/Unapproved Product(s) Discussion

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.


The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Supported by independent educational grants from Allergan, Merck, Neurocrine Biosciences, Sage Therapeutics, Shire, and Sunovion.

AAPA offers no returns or refunds for online CME activities purchased through the AAPA store. All sales are final.

Type:     Internet Activity (Enduring Material)
301 Registered Users